|
1
|
Han W and Li J: Structure-activity
relationship analysis of 3-phenylpyrazole derivatives as androgen
receptor antagonists. J Biomol Struct Dyn: 1-10, Jul 5, 2019 (Epub
ahead of print).
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fendler A, Jung M, Stephan C, Honey RJ,
Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K and Yousef
GM: miRNAs can predict prostate cancer biochemical relapse and are
involved in tumor progression. Int J Oncol. 39:1183–1192.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pereira-Lourenço M, Vieira E, Brito D,
Peralta JP, Godinho R, Conceiçao P, Reis M, Rabaça C and Sismeiro
A: Influence of sociodemographic factors on treatment's choice for
localized prostate cancer in Portugal. Arch Ital Urol Androl.
92:45–49. 2020.
|
|
5
|
van Brussel JP and Mickisch GH: Multidrug
resistance in prostate cancer. Onkologie. 26:175–181.
2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sturge J, Caley MP and Waxman J: Bone
metastasis in prostate cancer: Emerging therapeutic strategies. Nat
Rev Clin Oncol. 8:357–368. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chi KN, Bjartell A, Dearnaley D, Saad F,
Schröder FH, Sternberg C, Tombal B and Visakorpi T:
Castration-resistant prostate cancer: From new pathophysiology to
new treatment targets. Eur Urol. 56:594–605. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cookson MS, Lowrance WT, Murad MH and
Kibel AS: Castration-resistant prostate cancer: AUA guideline
amendment. J Urol. 193:491–499. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512.
2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bolten CJ, Heinzle E, Müller R and
Wittmann C: Investigation of the central carbon metabolism of
Sorangium cellulosum: Metabolic network reconstruction and
quantification of pathway fluxes. J Microbiol Biotechnol. 19:23–36.
2009.PubMed/NCBI
|
|
11
|
Tyszka-Czochara M, Konieczny P and Majka
M: Recent advances in the role of AMP-activated protein kinase in
metabolic reprogramming of metastatic cancer cells: Targeting
cellular bioenergetics and biosynthetic pathways for anti-tumor
treatment. J Physiol Pharmacol. 69:2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chaneton B and Gottlieb E: Rocking cell
metabolism: Revised functions of the key glycolytic regulator PKM2
in cancer. Trends Biochem Sci. 37:309–316. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang J, Wang H, Liu A, Fang C, Hao J and
Wang Z: Lactate dehydrogenase A negatively regulated by miRNAs
promotes aerobic glycolysis and is increased in colorectal cancer.
Oncotarget. 6:19456–19468. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han
J, Jeong SI, Kang MJ, Kim NH, Kim HJ and Chi SG: Caveolin-1
increases aerobic glycolysis in colorectal cancers by stimulating
HMGA1-mediated GLUT3 transcription. Cancer Res. 72:4097–4109.
2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li
X, Yang G, Liu X, Yao L, et al: Tumor suppressor NDRG2 inhibits
glycolysis and glutaminolysis in colorectal cancer cells by
repressing c-Myc expression. Oncotarget. 6:26161–26176.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L
and Jiang F: PKM2 and cancer: The function of PKM2 beyond
glycolysis. Oncol Lett. 11:1980–1986. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liang J, Cao R, Zhang Y, Xia Y, Zheng Y,
Li X, Wang L, Yang W and Lu Z: PKM2 dephosphorylation by Cdc25A
promotes the Warburg effect and tumorigenesis. Nat Commun.
7(12431)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Luan W, Wang Y, Chen X, Shi Y, Wang J,
Zhang J, Qian J, Li R, Tao T, Wei W, et al: PKM2 promotes glucose
metabolism and cell growth in gliomas through a mechanism involving
a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget. 6:13006–130018.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang
XA, Mu J, Hu YP, Jiang L, Dong P, et al: Up-regulation of PKM2
promote malignancy and related to adverse prognostic risk factor in
human gallbladder cancer. Sci Rep. 6(26351)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang HS, Zhang FJ, Li H, Liu Y, Du GY and
Huang YH: Tanshinone ⅡA inhibits human esophageal cancer cell
growth through miR-122-mediated PKM2 down-regulation. Arch Biochem
Biophys. 598:50–56. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu Q, Zhang M, Tu J, Pang L, Cai W and Liu
X: MicroRNA-122 affects cell aggressiveness and apoptosis by
targeting PKM2 in human hepatocellular carcinoma. Oncol Rep.
34:2054–2064. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Guo M, Zhao X, Yuan X, Jiang J and Li P:
MiR-let-7a inhibits cell proliferation, migration, and invasion by
down-regulating PKM2 in cervical cancer. Oncotarget. 8:28226–28236.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Taniguchi K, Sugito N, Kumazaki M,
Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama
K and Akao Y: MicroRNA-124 inhibits cancer cell growth through
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett.
363:17–27. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rigoutsos I: New tricks for animal
microRNAS: Targeting of amino acid coding regions at conserved and
nonconserved sites. Cancer Res. 69:3245–3248. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gandellini P, Profumo V, Casamichele A,
Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M,
Colecchia M, Pozzi S, et al: miR-205 regulates basement membrane
deposition in human prostate: Implications for cancer development.
Cell Death Differ. 19:1750–1760. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hudson RS, Yi M, Esposito D, Glynn SA,
Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH,
et al: MicroRNA-106b-25 cluster expression is associated with early
disease recurrence and targets caspase-7 and focal adhesion in
human prostate cancer. Oncogene. 32:4139–4147. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Boll K, Reiche K, Kasack K, Mörbt N,
Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn
F and Hackermüller J: MiR-130a, miR-203 and miR-205 jointly repress
key oncogenic pathways and are downregulated in prostate carcinoma.
Oncogene. 32:277–285. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Martens-Uzunova ES, Jalava SE, Dits NF,
van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T,
Visakorpi T and Jenster G: Diagnostic and prognostic signatures
from the small non-coding RNA transcriptome in prostate cancer.
Oncogene. 31:978–991. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Musumeci M, Coppola V, Addario A, Patrizii
M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni
M, Collura D, et al: Control of tumor and microenvironment
cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene.
30:4231–4242. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Takayama K, Tsutsumi S, Katayama S,
Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A,
Ikeo K, et al: Integration of cap analysis of gene expression and
chromatin immunoprecipitation analysis on array reveals genome-wide
androgen receptor signaling in prostate cancer cells. Oncogene.
30:619–630. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang X, Zhang H, Bai M, Ning T, Ge S, Deng
T, Liu R, Zhang L, Ying G and Ba Y: Exosomes serve as nanoparticles
to deliver anti-miR-214 to reverse chemoresistance to cisplatin in
gastric cancer. Mol Ther. 26:774–783. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pan C, Wang X, Shi K, Zheng Y, Li J, Chen
Y, Jin L and Pan Z: MiR-122 reverses the doxorubicin-resistance in
hepatocellular carcinoma cells through regulating the tumor
metabolism. PLoS One. 11(e0152090)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kishikawa T, Otsuka M, Tan PS Ohno M, Sun
X, Yoshikawa T, Shibata C, Takata A, Kojima K, Takehana K, et al:
Decreased miR122 in hepatocellular carcinoma leads to
chemoresistance with increased arginine. Oncotarget. 6:8339–8252.
2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
He J, Xie G, Tong J, Peng Y, Huang H, Li
J, Wang N and Liang H: Overexpression of microRNA-122 re-sensitizes
5-FU-resistant colon cancer cells to 5-FU through the inhibition of
PKM2 in vitro and in vivo. Cell Biochem Biophys. 70:1343–1350.
2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fujita Y, Kojima K, Hamada N, Ohhashi R,
Akao Y, Nozawa Y, Deguchi T and Ito M: Effects of miR-34a on cell
growth and chemoresistance in prostate cancer PC3 cells. Biochem
Biophys Res Commun. 377:114–119. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Singh S, Chitkara D, Mehrazin R, Behrman
SW, Wake RW and Mahato RI: Chemoresistance in prostate cancer cells
is regulated by miRNAs and Hedgehog pathway. PLoS One.
7(e40021)2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Li J, Yang X, Guan H, Mizokami A, Keller
ET, Xu X, Liu X, Tan J, Hu L, Lu Y and Zhang J: Exosome-derived
microRNAs contribute to prostate cancer chemoresistance. Int J
Oncol. 49:838–846. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shi G, Ye D, Yao X, Zhang SL, Dai B, Zhang
HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ and Ma CG: Involvement of
microRNA-21 in mediating chemo-resistance to docetaxel in
androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin.
31:867–873. 2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods.
25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Egawa T, Kubota T, Suto A, Otani Y,
Furukawa T, Watanabe M, Kumai K and Kitajima M: Docetaxel enhances
the cytotoxicity of anthracyclines by increasing intracellular drug
accumulation. Oncol Rep. 9:777–781. 2002.PubMed/NCBI
|
|
43
|
Lin W, Miao Y, Meng X, Huang Y, Zhao W and
Ruan J: miRNA-765 mediates multidrug resistance via targeting BATF2
in gastric cancer cells. FEBS Open Bio: Mar 12, 2020 (Epub ahead of
print).
|
|
44
|
Hong ST, Lin H, Wang CS, Chang CH, Lin
AMY, Yang JCH and Lo YL: Improving the anticancer effect of
afatinib and microRNA by using lipid polymeric nanoparticles
conjugated with dual pH-responsive and targeting peptides. J
Nanobiotechnology. 17(89)2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hong BS, Ryu HS, Kim N, Kim J, Lee E, Moon
H, Kim KH, Jin MS, Kwon NH, Kim S, et al: Tumor Suppressor
miRNA-204-5p regulates growth, metastasis, and immune
microenvironment remodeling in breast cancer. Cancer Res.
79:1520–1534. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z,
Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate
cancer cells proliferation and migration and enhances their
sensitivity to docetaxel through suppression of KRAS. Mol Cell
Biochem. 350:207–213. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bian Z, Li L, Tang R, Hou DX, Chen X,
Zhang CY and Zen K: Identification of mouse liver
mitochondria-associated miRNAs and their potential biological
functions. Cell Res. 20:1076–1078. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Liu C, Zhang L, Huang Y, Lu K, Tao T, Chen
S, Zhang X, Guan H, Chen M and Xu B: MicroRNA-328 directly targets
p21-activated protein kinase 6 inhibiting prostate cancer
proliferation and enhancing docetaxel sensitivity. Mol Med Rep.
12:7389–7395. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010.PubMed/NCBI View Article : Google Scholar
|
